Cargando…

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study

BACKGROUND: We investigated whether the administration of maintenance doses of interferon prevented hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. METHODS: Study 1: A multicenter, retrospective, cooperative study was carried out to determine whether long-term administration of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izumi, Namiki, Asahina, Yasuhiro, Kurosaki, Masayuki, Yamada, Gotaro, Kawai, Tsutomu, Kajiwara, Eiji, Okamura, Yukishige, Takeuchi, Takayuki, Yokosuka, Osamu, Kariyama, Kazuya, Toyoda, Joji, Inao, Mie, Tanaka, Eiji, Moriwaki, Hisataka, Adachi, Hiroshi, Katsushima, Shinji, Kudo, Masatoshi, Takaguchi, Kouichi, Hiasa, Yoichi, Chayama, Kazuaki, Yatsuhashi, Hiroshi, Oketani, Makoto, Kumada, Hiromitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2012
Materias:	Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618412/ https://www.ncbi.nlm.nih.gov/pubmed/22875473 http://dx.doi.org/10.1007/s00535-012-0641-9

Ejemplares similares

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
por: Takehara, Tetsuo, et al.
Publicado: (2020)

Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids
por: Paulo, Joao A, et al.
Publicado: (2012)

Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes
por: Tummala, Pavan, et al.
Publicado: (2013)

A Pilot Study to Develop a Diagnostic Test for Pancreatic Ductal Adenocarcinoma Based on Differential Expression of Select miRNA in Plasma and Bile
por: Cote, Gregory A, et al.
Publicado: (2014)

Algorithm to determine the outcome of patients with acute liver failure: a data-mining analysis using decision trees
por: Nakayama, Nobuaki, et al.
Publicado: (2012)

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
por: Takehara, Tetsuo, et al.
Publicado: (2018)

Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus
por: Tahata, Yuki, et al.
Publicado: (2023)

Transition in the etiology of liver cirrhosis in Japan: a nationwide survey
por: Enomoto, Hirayuki, et al.
Publicado: (2019)

The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan
por: Enomoto, Hirayuki, et al.
Publicado: (2020)

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
por: Okita, Kiwamu, et al.
Publicado: (2014)

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
por: Okita, Kiwamu, et al.
Publicado: (2014)

Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021)

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021)

Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury
por: Lleo, Ana, et al.
Publicado: (2022)

Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States
por: Kim, Donghee, et al.
Publicado: (2023)

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study
por: Iavarone, Massimo, et al.
Publicado: (2023)

COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization
por: Stroffolini, Tommaso, et al.
Publicado: (2023)

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
por: Tateishi, Ryosuke, et al.
Publicado: (2018)

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study
por: Kawaguchi, Takumi, et al.
Publicado: (2012)

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019)

Impact of early cholecystectomy on the readmission rate in patients with acute gallstone cholangitis: a retrospective single-centre study
por: Hoilat, Gilles Jadd, et al.
Publicado: (2021)

Interventional treatment of biliodigestive anastomosis leaks with a modified percutaneous transhepatic cholangiodrainage
por: Lopez Benitez, Ruben, et al.
Publicado: (2022)

Factors predicting 30-day mortality after ERCP in patients with inoperable malignant hilar biliary obstruction: a single tertiary referral centre experience and systematic review
por: On, Wei, et al.
Publicado: (2022)

Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment
por: Fasullo, Matthew, et al.
Publicado: (2022)

Cost-effectiveness analysis of antibiotic prophylaxis versus no antibiotic prophylaxis for acute cholecystectomy
por: Satheeskaran, Maya, et al.
Publicado: (2023)

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
por: Naganuma, Atsushi, et al.
Publicado: (2019)

Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution
por: Oshita, Ko, et al.
Publicado: (2020)

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
por: Kumada, Hiromitsu, et al.
Publicado: (2016)

Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
por: Hayashi, Norio, et al.
Publicado: (2014)

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
por: Chayama, Kazuaki, et al.
Publicado: (2017)

Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)
por: Sakaida, Isao, et al.
Publicado: (2020)

Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study
por: Tateishi, Ryosuke, et al.
Publicado: (2014)

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
por: Hayashi, Norio, et al.
Publicado: (2015)

High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
por: Kumada, Takashi, et al.
Publicado: (2013)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qh1oeb3ofhkrd6pusurh1m9sl0